StockData

Ultragenyx Pharmaceutical vs TG Therapeutics

RARE and TGTX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How RARE and TGTX compare

TG Therapeutics is the larger company, worth 5.8 times as much as Ultragenyx Pharmaceutical ($9.6B against $1.6B).

TG Therapeutics grew revenue faster over the last twelve months (76.1% versus 17.5% for Ultragenyx Pharmaceutical).

TG Therapeutics keeps more of each dollar of sales as profit, with a net margin of 55.2% compared with −81.7% at Ultragenyx Pharmaceutical.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricRARETGTX
Size and price
Market cap$1.6B$9.6B
Share price$16.70$62.71
Change, 1 year−49.5%102%
Change, 5 years−78.2%162%
Beta (5Y)2.120.47
Employees1,371399
StockData Score
Total score99
Valuation score11
Growth score22
Performance score14 (better)
Health score5 (better)2
Dividend score00
Valuation
P/E–22.9×
P/S2.3× (better)12.0×
P/B–15.9×
EV/EBITDA–71.3×
P/FCF–552×
FCF yield−29.7%0.18% (better)
Fair value–$60.66
Margin of safety–−3.4%
Growth
Revenue growth (TTM)17.5%76.1% (better)
Revenue growth, 5Y average19.9%427% (better)
Net income growth (TTM)–630%
EPS growth (TTM)–641%
Profitability
Gross margin–82.4%
Operating margin−73.6%17.1% (better)
Net margin−81.7%55.2% (better)
FCF margin−68.2%2.2% (better)
Return on equity–100%
Return on invested capital–27.8%
Financial health
Debt / equity–1.23
Net debt / EBITDA–0.98
Interest coverage–3.6×
Current ratio1.734.27 (better)
Altman Z-score−5.266.07 (better)
Piotroski F-score5 (better)4
Dividends and buybacks
Buyback yield–1.9%
Shareholder yield0.00%1.9% (better)
Ownership
Held by institutions108%72.6%
Held by insiders4.0%16.1%
Insider net buying, 12 months−$3.8M−$275K (better)
Short interest, % of float25.0%22.4%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.